Agilon Health (AGL) Reports Q3 Loss, Lags Revenue Estimates

Financial Performance - Agilon Health reported a quarterly loss of $0.29 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.06 per share a year ago, indicating a significant earnings surprise of -190% [1] - The company posted revenues of $1.45 billion for the quarter ended September 2024, missing the Zacks Consensus Estimate by 1.29%, and this represents an increase from year-ago revenues of $1.22 billion [2] - Over the last four quarters, Agilon has surpassed consensus EPS estimates only once, and it has topped consensus revenue estimates just once as well [2] Stock Performance - Agilon shares have declined approximately 77.1% since the beginning of the year, contrasting sharply with the S&P 500's gain of 24.3% [3] - The current Zacks Rank for Agilon is 4 (Sell), indicating expectations for the stock to underperform the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $1.47 billion, and for the current fiscal year, it is -$0.39 on revenues of $6.02 billion [7] - The estimate revisions trend for Agilon is currently unfavorable, which could change following the recent earnings report [6] Industry Context - The Medical Services industry, to which Agilon belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8] - Another company in the same industry, Aclarion, Inc. (ACON), is expected to report a quarterly loss of $0.18 per share, reflecting a year-over-year change of +90.6% [9]